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Abstract: The protio enol lactone 4-Phenyl-6-
methylidinetetrahydro-2-pyranone (3) has been shown in our labs 
to be an alternate substrate inhibitor of a-chymotrypsin by its
formation of a stable acyl enzyme In this study, the synthesis
of alpha and gamma methyl derivatives of (3) is described. 
Initial inhibition tests have been performed on a-chymotrypsin
with the alpha and gamma derivatives with the gamma derivatives 
appearing to inhibit the enzyme but having an approximately six­
fold faster rate of deacylation than (3) . The results from the 
studies on the alpha methyl have been inconclusive so far because 
of complications from slow acylation rates.
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I. Introduction
The study of enzymes and their mechanisms is of great 
importance and interest because of the vital role they play in 
almost every biological process. These protein structures each 
have a unique structure which is very specific for the molecules 
they act upon within the organism. It has been found that certain 
clinical diseases* etiologies are enzyme systems that are either 
no longer functioning or are no longer properly inhibited. Many 
researchers hope that by elucidating an enzyme's structure and 
mechanism they can find a way to control or correct that enzyme's 
activity. Much of the research done with enzymes is directed 
towards enzyme inhibition as a means of controlling enzymes and 
thus being theraputically helpful.2 The clinical success of this 
branch of research can be seen today with drugs that can inhibit 
angiotensin converting enzyme (ACE inhibitors) as a means for 
controlling high blood pressure,3 and drugs which can inhibit HMG- 
CoA reductase as a means for reducing serum cholesterol levels.4
Although there are many classes of enzyme inhibitors, many 
are not suitable for use in vivo because of the need for high 
potency, high specificity, and low toxicity. Most reversible 
inhibitors are not specific ,or potent enough to be used
clinically. Irreversible inhibitors, such as affinity labels, are
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usually too toxic to use because of their high reactiviy, For use 
in vivo, a class of inhibitors known as reversible and 
irreversible mechanism-based inhibitors seem to have the best 
characteristics. These compounds bind to the active site of the 
targeted enzyme like a competitive inhibitor but then undergo 
further reaction with the enzyme during the course of the enzyme’s 
catalytic activity or undergo succeeding steps very slowly. This 
makes this class of inhibitor highly specific because their 
inhibitory mechanism is a function of both binding specifically to 
the enzyme and the specific catalytic mechanism of the targeted 
enzyme.
Development^ of serine protease inhibitors. The focus of research 
within our labs is on the serine proteases and the synthesis of 
potential serine protease inhibitors. Proteases are a group of 
enzymes which catalyze the hydrolysis of peptide linkages. 
Proteases play a large role in digestion and also are involved 
with such physiological processes as blood coagulation, blood 
pressure regulation, and fertilzation. These enzymes are also 
associated with diseases such as arthritis, pulmonary emphysema, 
and acute pancreatitis. A subgroup of the protease family of 
enzymes is the serine proteases. The serine proteases include 
such important enzymes as chymotrypsin, trypsin, and elastase, all 
of which are similar in many respects.5 These enzymes catalyze 
the cleavage of an internal peptide bond of a protein or 
polypeptide and are thus classified as endopeptidases. They all 
contain an active site, serine residue and have the same amino acid
sequence around this serine (Gly-Asp~Ser-Gly-Gly-Pro) which means 
that these serine proteases all have nearly identical catalytic 
mechanisms. a-Chymotrypsin is a serine protease that is
convenient for study because of the ability to purchase this 
enzyme in large quantities and high purity, and because of its 
well studied mechanism of action.6 Our group has developed serine 
protease inhibitors based on Rando's proposal that haloenol 
lactones could act as suicide substrate inhibitors by releasing a 
hidden reactive functional group upon acylation, an a-haloketone.7
This reactive functional group, which is attached by the inhibitor 
to the active site serine, could then react with nucleophilic 
residues near the active site. Thus, even after deacylation, the 
enzyme would remain inhibited. The haloenol butyrolactones (1) and 
valerolactones (2) have been synthesized in our laboratories and 
have been shown to be potent mechanism-ba3ed irreversible 
inhibitors of a-chymotrypsin.8”10
_ jO DI
V < 0 X= I, Br
U y  r = ph, Np '
s ?
(1) (2)
While studying the optimal positioning of the aryl
substituent for the haloenol lactones (1) and (2), workers in our
A
laboratories discovered a new alternate substrate inhibitor of Ot-
chymotrypsin, 4-Phenyl-6-methylidinetetrahydro-2-pyranone (3).11
Alternate substrate inhibitors are reversible mechanism-based 
which bind well with the enzyme and react rapidly in the initial 
catalytic event but then undergo the final catalytic step very 
slowly. The slow rate that the enzyme turns over these inhibitors 
is responsible for their inhibitory properties.
It has been theorized in our laboratories that the stability 
of the acyl enzyme formed by (3) is a result of a twisted acyl 
enzyme. With the carbonyl in a twisted position, a water molecule 
cannot be properly oriented in to attack the carbonyl carbon which 
leads to a slow rate of deacylation. This twisted acyl enzyme 
conformation is limited to the R enantiomer, however, and is not 
seen with the S enantiomer of (3), with the R enantiomer having a 
60-70 fold slower rate of deacylation.12 The acyl enzyme of a 
good substrate deacylates rapidly with the main chain -NH- groups 
of serine 195 and glycine 193 stabilizing the carbonyl oxygen of 
the acyl group linked to serine 195.13 The acyl enzyme which forms 
from the S enantiomer seems to have this orientation and is open 
to attack from neighboring water molecules. In the case of the R
(3)
enantiomer, however, it has been theorized that the stabilizing 
hydrogen binding site of the main chain -NH- groups is occupied by 
the carbonyl of the methyl ketone moiety released upon acylation 
and not the carbonyl of the acyl group. Alterations of (3) which 
expose a non-polar, isosteric funcional group upon acylation do 
not form as stable of an acyl enzyme as (3), confirming the 
importance of the methyl ketone.14 Recently, workers in our group 
performed conformational analysis and energy minimization 
calculations on the acyl enzyme formed by the two enantiomers of 
(3).15 These calculations showed that the acyl enzyme formed from 
the S enantiomer has a minimum energy in the normal conformation 
while the acyl enzyme formed by the R enantiomer has a minimized 
energy in the twisted state. These calculations go along »*ith the 
observation of a more stable enzyme for the R enantiomer.
Goals of this work. Through modeling techniques, it was deduced 
that gamma methyl derivatives of (3) might provide a more stable 
acyl enzyme than (3).16 It was also thought that a methyl 
substituent at the alpha position could produce interesting 
results. By synthesizing these compounds it was hoped that better 
alternate substrate inhibitors of a-chymotrypsin might be
obtained. In addition, the kinetic data obtained from these 
compounds might provide more information for our model of acyl 
enzyme stabilization.
In this study, the synthesis of these derivatives is 
described and initial kinetic data on deacylation rates is given.
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II. Results and Discussion
Chemical Synthesis.
For the inactivation studies of a-chymotrypsin, the 
following enol lactones were prepared and separated into cis and 
trans diastereomers: 5-Methyl-4-phenyl-6-methylene-tetrahydro-2- 
pyranone [cis diastereomer (y-Me cis), trans diastereomer (y-Me
4
trans)], and 3-Methyl-4 ■phenyl-6-methylene-tetrahydro-2-pyranone 
[cis diastereomer (a-Me cis), trans diastereomer (a-Me trans)].
7 (y-Me cis) 8 (y-Me trans)
14 (a-Me trans)
A. Scheme I- g-Methyl derivative of (3).
The initial ester (4) in the reaction sequence was prepared
by the method of Stella17 initially by the addition of crotyl zinc
6
bromide to diethyl benzalmalonate to produce the diester in 33% 
yield. Some of the starting diethyl benzalmalonate and some of 
the 1,2 addition product were impurities, but this product was 
carried on to the decarboethoxylation step which was performed in 
DMSO/NaCl (aq.). The ester was then saponified in 5% potassium 
hydroxide/methanol to the acid (5) in 93% yield. The alkynoic acid 
precursor (6) was then prepared by bromination followed by 
dehydrobromination of (5) in a sodamide suspension in ammonia 
according to the general methods of Brandsma.1 8 
Dehydrobromination was attempted in many systems such as 
methanolic KOH and ethanolic sodium ethoxide, but the vinyl 
bromide proved to be very stable. (5) was isolated in 33% yield. 
This alkynoic acid was then cyclized with mercuric 
trifluoroacetate in 55% yield to the enol lactones (7,8) by the 
procedure developed in our labs.15
B. Scheme II- a-Methyl derivative of (3).
The initial ester in this scheme (9) was prepared according 
to the method of Stella17 by the initial addition of allyl zinc 
bromide to diethyl benzalmalonate followed by decarboethoxylation 
with DMSO/NaCl aq. Product (9) was isolated in 36% overall yield. 
The ester was then methylated via an enolate addition with LDA as 
the base and methyl iodide as the electrophile with the methylated 
product (10) recovered in 71% yield. The methylated ester was then 
saponified to the acid (11) with 5% potassium hydroxide/methanol 
in 89% yield. The alkynoic acid was then formed by bromination
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Scheme I
DMSO
NaCl, H20 
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f
5% KOH 
MeOH 93%
1. Br2, Et20
2. NaNH2, NH3 
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7 (y-Me cis)
8 (y-Me trans)
Scheme II
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13 (o-Me cis) 14 <a-Me trans)
followed by dehydrobrominatlon in a sodamide suspension in ammonia 
according to the general methods of Brandsma.10 The alkynoic acid 
(12) was then cyclized with mercuric trifluoroacetate to the enol 
lactones (13, 14) by the procedure developed in our labs.19 The 
impurity that is present in 13% by GC appears to be the isomerized 
form of (13, 14):
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Evidence which seems to indicate this compound as the impurity 
includes the ability to obtain a good elemental analysis of 
diastereomer I of (13, 14) despite the prescence of the impurity,
and peaks in the NMR spectrum that would indicate this compound: 
(360 MHz) 5 (ppm) .99 (d, J- 6.9 Hz, -C(-0)CH(Cfl3)CH(Ph)-), 2.00
(singlet, -CH-C(CJl3)0-), 5.2 (d, peaks too small too measure
coupling constant, (-CH-C (CH3)0-) . In the future, a gas 
chromatography/mass spectrum will be performed to further 
determine that the impurity is (15).
C. Determination of cis and trans diastereomers. The enol 
lactones were modeled using Macromodel, and the theoretical 
coupling constants between the two methine protons in the lactone 
ring were calculated.20 The results of these calculations are as 
follows: y-Me cis J- 3.7 Hz
y-Me trans J- 12.1 Hz
a-Me cis J~ 4,2 Hz
a-Me trans J« 12,5 Hz
NMR spetrum were taken with a Nicolet 360 (360 MHz)
spectrometer and coupling constants between the methine protons 
were extracted by decoupling various signals.21
g~Me, Diastereomer I- The methyl protons of this compound were 
decoupled, and the coupling constant of the methine proton 
adjacent to this methyl was measured to be 8.9 Hz. The methine
proton adjacent to the phenyl could not be separated from the 
methylene protons for an effective decoupling of the methylene 
protons to take place.
g-Me, Diastereomer II- The methyl protons of this diastereomer 
were decoupled, and the coupling constant of the methine proton 
adjacent to the methyl group was measured and found to be 4.3 Hz. 
The methylene protons of the lactone ring were then decoupled and 
the coupling constant to the methine proton adjacent to the phenyl 
substituent was determined to be 2.8 Hz. This coupling constant 
is lower than the one found for the other methine most likely 
because some of the irradiation of the methylene protons spilled 
over on the nearby methine proton adjacent to the methyl group and 
distorted the coupling constant.
From this data, it was concluded that diastereomer II was the 
cis diastereomer because of the lower coupling constant which 
closely matches the calculated theoretical values. Diastereomer I 
was determined to be the trans diastereomer because of its larger 
coupling constant (J- 8.9 Hz) which is much closer than
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diastereomer II to the calculated coupling constant of the trans 
diastereomer.
a-Me, Diastereomer II- The signals for this compound were 
complicated as one of the methylene protons overlapped with the 
methine proton adjacent to the methyl group, however after 
irradiation of the methyl protons, the coupling constant between 
the methines was determined to be J= 6.0 Hz.
a-Me, Diastereomer I- With this diastereomer, the methine 
coupling constant could not be determined because of extensive 
overlap between the two methine protons and the two methylene 
protons. To separate these signals, a shift reagent was tried but 
separation was not achieved.
While the coupling constant of diastereomer II would seem to 
indicate that it is the trans diastereomer, further NMR testing of 
diastereomer I must be done before the assignment of cis and trans 
to these diastereomers can be made.
D. Initial kinetic data for (g-Me cis), (g-Me trans), (a-Me cis), 
and (a-Me trans).
a.) Rate constant of deacylation !<<*- The rate constant of 
deacylation for alternate substrate inhibitors of a-chymotrypsin
can conveniently obtained through a proflavin displacement 
assay.22 Proflavin binds strongly to the enzyme, but when the 
acyl enzyme forms, the proflavin binding site is altered, and the 
proflavin is released. The maximum difference in absorbance 
between unbound proflavin and the proflavin-enzyme complex occurs
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at 4 66 nm, and absorbance measurement at this wavelength can be 
used to monitor the rate of deacylation.23
The inhibitor is added to a prepared solution of a-
chymotrypsin and proflavin and the aborbance change was monitored 
over time at a wavelength of 466 nm. An initial decrease in 
absorbance is caused by the inhibitor forming the acyl enzyme and 
displacing the proflavin. A gradual increase in absorbance then 
occurs which is the deacylation of the acyl enzyme followed by the 
reassociation of proflavin and enzyme. The rate constant of
deacylation was then calculated from the curve.
The enol lactones (y-Me cis), (y-Me trans), (a-Me cis), and 
(a~Me trans) are all racemic mixtures of R and S enantiomers. As 
stated before, in previous studies the R enantiomer was the more 
slowly deacylating enantiomer, and the same results were expected 
with the above protio enol lactones. With (3), the proflavin 
displacement assay gave a biphasic curve, and rate constants of 
both the quickly deacylating (S) and the slowly deacylating (K) 
enantiomers were obtained because of the large difference between 
the two.
In initial studies of (y-Me cis) and (y-Me trans), a clearly 
biphasic curve was not observed. Although the initial rates of 
deacylation seen from the curves seem to indicate that a more 
quickly deacylating enantiomer might be present, more tests must 
be run to determine this. In addition, a very long assay was 
performed with the cis diastereomer (7), (99,000 seconds), to
determine if a more slowly deacylating enantiomer was present but
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none were seen. This means that either the rapidly deacylating 
inhibitor is too rapid to be seen, that one of the enantiomers is 
not acylating, or that the enantioselectivity is not great enough 
to see a difference between the two. Initial values of K<j taken 
from the curve were:
y-Me cis 7 Kd- .0168 min-1
y-Me trans 8 Kd- .0181 min-1
(3)12 Kd- .0029 min-1
These initial values of K<* indicate that the gamma methyl 
derivatives of (3) form less stable acyl enzymes than (3) . Much 
more work must be done, however, to determine the deacylation 
rates of the separate enantiomers.
The alpha methyl derivatives of (3) show complicated graphs 
because of slower acylation rates. As with the gamma methyl 
derivatives, the graphs do not appear to be clearly biphasic, but 
more assays are to be done to determine if there is possibly a 
more slowly deacylating enantiomer than is seen with the initial 
results. A proflavin assay run by "method BM might possibly give 
better results by eliminating unacylated enol lactone.24 Tests 
must also be run to determine if all the enol lactone is acylating 
with the enzyme, or if there is possibly an enantiomer which turns 
over too quickly to be seen. A deacylation rate of the racemic 
mixture could not be. determined for the diastereomer II of the
alpha methyl derivatives, but it appears to be slower than 
diastereomer I. The initial deacylation rate of diastereomer I 
was determined to be ,0186 min**1,
E. Inactivation studies of other serine proteases with y-Me cis 
(7) and y-Me trans (8).
Assays of the gamma methyl derivatives were done to determine 
if they had inhibitory effects against other serine proteases such 
as human leukocyte elastase (HLE), trypsin, and porcine pancreatic 
elastase (PPE),25
% Activity of enzyme after 90 min, in presence of inhibitor
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3f-Me ala (7) y-Me trana (8) (3)
HLE 0.13 0.36 69.0
Trypsin 3.6 22.2 17.5
PPE 10.7 48.6 94.4
The gamma methyl derivatives of (3) appear to be better 
inhibitors of these serine proteases than (3), especially of the 
two types of elastase.
F. Summary- The synthesis of the alpha and gamma methyl 
derivatives of (3) was accomplished. Three of the compounds have 
been isolated in pure form with the fourth (a-Me DI) containing a
single impurity which appears to be the isomerized version of the
enol lactones (15). Initial kinetic data shows that the gamma 
methyl derivatives do not seem to form as stable an acyl enzyme as 
(3), but more assays must be done. The alpha methyl derivatives 
show more complicated kinetics because of slower acylation rates, 
but diastereomer II looks promising as an inhibitor of a-
chymotrypsin. The gamma methyl derivatives have also showed 
surprising inhibition of HLE, trypsin, and PPE.
G. Future Work.
In the future, more studies will be attempted to gain more 
definitive evidence for the relative orientaion (cis or trans) of 
the substituents on the disubstituted enol lactones. The 
definite deacylation rates of each of the four enol lactones will 
also be calculated through further deacylation rate studies. The 
possibility of these enol lactones being inhibitors of other 
serine proteases such as HLE, trypsin, and PPE will also be 
explored.
It is also hoped that the racemic mixtures of the enol 
lactones will be able to be resolved into enantiomerically pure 
compounds. The racemic mixture of (3) has been resolved in our 
laboratories through use of a phenyl glycinol derivative and this 
route will be attempted in the future.26 Chiral HPLC columns are 
also being looked into as possible methods of resolving these 
compounds.
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III. Experimental
A. Chemical
General. Analytical thin layer chromatography was performed 
using 0.25 mm Merck silica gel 60 f-254 glass backed plates. 
Compounds were made visible using iodine vapor, ultraviolet 
light, or phosphomolybdic acid. Flash chromatography was 
performed according to the method of Still^ using Woelm 32-63 Jim
silica gel.
Proton nuclear magnetic resonance NMR) spectra were
recorded on Varian XL-200 (200 MHz), Nicolet 360 (360 MHz), or
General Electric 500 (500 MHz). Chemical shifts in the spectra 
are reported as parts per million downfield from 
tetramethylsilane as an internal standard (5 scale). In this 
section, the NMR data are presented in the form: 6 value of 
signal (peak multiplicity, integrated number of protons, coupling 
constant (if one is present), and assignment). For many 
compounds that are characterized in this section, both 
diastereomers are present and are reported together in the same 
NMR. For the integration, the number of protons from each 
diastereomer were added together so, for example, the aromatic 
protons are reported as ten protons instead of five. Low
resolution electron impact mass spectra were obtained on a Varian
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CH-5 mass spectometer at 70 ev. The data reported are in the form 
of: m/z (intensity relative to base peak-100). High resolution 
mass spectra (HRMS) were obtained by electron impact using a 
Varian MAT 731 spectrometer. Infrared spectra were obtained on a 
IBM IR/30S FTIR spectrometer and the data are presented as cnT* 
for diagnostic and prominent peaks. Elemental analyses were 
performed by the Microanalytical Service Laboratory of the 
University of Illinois School of Chemical Sciences. Melting 
points were determined on a Thomas-Hoover apparatus.
Solvents and reagents were obtained from the following 
commercial sources: Aldrich, Baker, Mallinckrodt, and Fisher. 
These products were used as received or purified as indicated. 
Tetrahydrofuran (THF) was distilled prior to use from sodium 
benzophenone ketyl. Methylene chloride was distilled prior to 
use from phosphorus pentoxide. Triethylamine (TEA) was distilled 
from calcium hydride and stored over NaOH. Diisopropyl amine was 
distilled from calcium hydride and stored over NaOH in a 
dessicator prior to use. n-Butyllithium as a hexane solution was 
titrated with diphenylacetic acid to determine the concentration 
of organic base present. Sodamide suspensions were prepared by the 
addition of sodium to liquid ammonia and the process was 
catalyzed with ferric nitrate. All reactions unless otherwise 
noted were carried out under a nitrogen atmosphere.
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Scheme I
Ethyl 4-methyl-3-phenyl-5-hexenoate (4) . This compound was 
prepared by the addition of crotyl zinc bromide to diethyl 
benzalmalonate (.1 mole) followed by decarboethoxylation in 
DMSO/NaCl(aq.) according to the method of Stella et. al 
Crotyl bromide was purified by drying with MgS04 followed by 
distillation. The diethyl benzalmalonate was purified by 
Kugelrohr distillation. The initial alkylation product was 
carried to the decarboethoxylation step after Kugelrohr 
distillation. After decarboethoxylation, the prescence of the 
apparent 1,2 addition product and ethyl cinnamate produced from 
unreacted diethyl benzalmalonate from the initial alkylation 
required the monoester to be purified first by Kugelrohr 
distillation followed by flash chromatography using 7.5% ethyl 
acetate/hexane. The ester (4) was a clear oil obtained in 33% 
overall yield. 1H NMR (CDCI3, 200 MHz) 5 7.11 to 7.31 <m, 10,
aromatic), 5.50 to 5.80 (m, 2, -CH-CH2), 4.89 to 5.11 (m, 4, - 
CH-CH2.), 3.97 (m, 4, -CO2CH2CH3), 3.15 (m, 2, -CH2Cfl(Ph) CH (CH3) - 
), 2.3 to 3.0 (m, 6, -CH2CH(Ph)CH(CH3)-) 1.10 (t, 3.2, J-7.1 Hz, 
C02CH2Ctt^ of greater diastereomer), 1.05 (t, 2.8, J-7.1 Hz,
C02CH2CHi of lesser diastereomer), .97 (d, 3.2 , j-6.5 Hz, -
CHCH(CH3)CH-CH2 of greater diastereomer), .80 (d, 2.8, J-6.7 Hz,
-CHCH(CH3)CH«CH2 of lesser diastereomer); mass spectrum, m/z 232 
(M+, 3), 177 (11), 176 (7), 144 (24), 1?5 (100), 105 (91), 77 
(77), 54 (61); IR (neat) 2975, 2930, 1734 (C-0), 1640 (C-C), 
1252, 1169 cm-1. Anal, calcd. for C15H20O2: C, 77.55; H, 8.68. 
Found: C, 77.57; H, 8.66.
4-Methyl-3-phenyl-5-hexenoic acid (5). The ester (1.5 g, 
6.47 mmol) was dissolved In a solution prepared from 40 ml of 5% 
aqueous potassium hydroxide and 78 ml methanol and stirred under 
nitrogen at room temperature for 4 hours. The methanol was 
removed in vacuo, and the basic aqueous phase was extracted with 
three portions of diethyl ether. The aqueous phase was then 
acidified with concentrated hydrochloric acid to a PH of 3. This 
solution was then extracted four times with ethyl acetate. The 
organic phases were dried (MgS04) and concentrated to give a
clear oil. This oil was then Kugelrohr distilled to a clear oil 
in 93% yield (1.23 g). 1H NMR (CDCL3, 200 MHz) 3 7.09 to 7.31
(m, 10, aromatic), 5.47 to 5.71 (m, 2, CH-CH2), 4.90 to 5.10 (m, 
4, CH-CH2), 3.11 (m, 2, -CH2CH(Ph)CH(CH3)-), 2.30 to 2.89 (m, 6, 
-CH2CH(Ph)Cfl(CH3)-), .94 (d, 3.4, ,>'6.5 Hz, -CHCH(CH3)CH-CH2 of
greater diastereomer), .78 (d, 2.6, J-6.7 Hz, -CHCH(CH3)CH«CH2 of 
lesser diastereomer); mass spectrum, m/z 204 (M+,10), 149 (63), 
148 (55), 145 (17), 144 (100), 107 (16); IR (neat) 3031, 2965, 
1707 (C-O), 1639 (C-C), : 153, 1418, 916 cm-1; Anal. Cald. for
C13H16O2: C, 76.44; H, 7.89. Found: C, 76.50; H, 7.92.
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4-Methyl3-pheryl-5-hexynoic acid (6) . This compound was 
prepared following the general procedure of Brandsma.17 The 
starting acid (.5 gram) was dissolved in 4 ml of diethyl ether 
and cooled to -20 °C. Added bromine (1.1 equiv., .14 ml) dropwise 
via syringe over twenty minutes. After the addition the solution 
was very difficult to stir due to a thick brown oil which came 
out of solution. This solution was allowed to warm to room 
temperature before adding to the sodamide suspension (488 mg of 
sodamide in 18 ml ammonia, 5 equiv.). The addition over ten 
minutes was done while sweeping the system with nitrogen to 
prevent ammonia from mixing with the acid in the addition funnel. 
The reaction was allowed to proceed while, unlike in Brandsma's 
method, a dry ice/acetone reflux condenser was used to prevent 
ammonia from boiling off. At two hours after the addition of 
orominated (5) to the sodamide suspension, the ammonia was 
allowed to boil off, and the remaining product was taken up in 70 
ml of water. The solution was acidified to a PH of 3 with 
concentrated HC1, extracted with four portions of ethyl acetate, 
dried (MgS04) and concentrated to an amber oil. The crude 
product was flashed using 40% ethyl acetate/hexane 1% acetic acid 
which was followed by Kugelrohr distillation. This produced a 
clear oil (164 mg, 33% yield). 1H NMR (CDC13, 200 MHz) S 8.54 (s,
2, acid), 7.17 to 7.27 (m, 10, aromatic), 2.60 to 3.17 (m, 8, 
H02CCtt2pini?*1) CH(CH3) -R), 2.16 (d, .6, J-2.1 Hz, acetelynic of 
lesser diastereomer) , 2.12 (d, 1.4, J»2.6 Hz, acetelynic of 
greater diastereomer), 1.03 (d, 6, J-7.0 Hz, methyl protons);
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mass spectrum m/z 202 (M+, 1.3), 149 (19), 143 (18), 142 (60),
107 (100), 79 (28), 77 (27); IR (neat) 3294, 2975, 2361, 1707
(C«0) , 1452, 1283 cm~^. Exact mass calcd. for C13H14O2 m/e
202.0994, obsd. m/e 202.0990.
5-Methyl-4-phenyl-6~methylene-tetrahydro-2~pyranone (7,8). 
This compound was prepared using methods developed earlier in our 
labs using mercuric trifluoroacetate. The alkynoic acid (218 
mg) was dissolved in 7 ml of dry methylene chloride. To this was 
added 46.1 mg (.1 equiv.) of mercuric trifluoroacetate, and the 
solution was stirred at room temperature for fifteen hours 
although the reaction appeared to be complete by gas 
chromatography at approximately four hours. The reaction was 
quenched with .saturated sodium bicarbonate and allowed to 3tir 
for ten minutes. The solution was then diluted with water and 
extracted four times with methylene chloride. The organic phases 
were kept, washed with water one time, dried (MgS04), and 
concentrated to a bright yellow oil. To purify and separate the 
cis and trans diastereomers, flash chromatography was performed 
using 15% ethyl acetate/hexane. Separation was achieved although 
not in great amounts because of the many mixed fractions that 
came off the column. Yield- 120 mg (55% yield) of a cloudy 
colorless oil.
Diastereomer I: trans (8)- Upper spot by TLC (Rf>® .32, 15% ethyl
acetate/hexane), 10.7 mg obtained pure from the column. 1H NMR 
(CDCI3, 360 MHz) 8 7,26 to 7.39 (m, 3, meta and para aromatic),
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7.17 (m, 2, ortho aromatic), 4.82 (t, 1, J-1.5 Hz, vinylic), 4.44 
(t, 1, J" 1.6 Hz, vinylic), 2.98 (m, 1, -CflHCH (Ph) CH (Me)-), 2.78 
(m, 2, -CHHCii(Ph)CH(Me)-) , 2.65 (m, 1, -CH2CH(Ph)CH(Me)-), 1.04
(d, 3, J= 6.6 Hz, methyl); mass spectrum m/z 202 (M+, 9), 174 
(5), 145 (9), 131 (100), 118 (22), 117 (28), 103 (25). Anal, 
calcd. for C13H14O2: C, 77.20; H, 6.98. Found: C, 77.19; H,
7.02.
Diastereomer II: cis (7)- Lower spot by TLC (Rf“ .24, 15%
ethyl acetate/hexane), 11.9 mg obtained pure from the column, Ifl 
NMR (CDCI3, 500 MHz) 8 7.29 to 7.38 (m, 3, meta and para
aromatic), 7.15 (m, 2, ortho), 4.75 (s, 1, vinylic), 4.24 (d, 1, 
J- 1.1 Hz, vinylic), 3.30 (m, 1, -CF2CH(Ph)CH(CH3>-)' 3-°° <m' 2' 
-CO2CH2.CH (Ph) -), 2.89 (m, 1, -CH2CH(Ph)Ctt(CH3)-), •98 <dd' 3'
6.7, 1.0 Hz, methyl); mass spectrum m/z 202 (M+r 9)/ 174 (3)'
158 (10), 145 (14), 131 (100), 118 (22), 117 (28), 103 (25).
Anal, calcd. for C13H14O2: C, 77.20; H, 6.98. Found: C, 77.25;
23
H, 7.04.
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Ethyl 3-Phenyl-5-hexenoate (9)- This compound was prepared 
by the addition of allyl zinc bromide to diethyl benzalmalonate 
followed by decarboethoxylation in DMSO/NaCl aq. according to the 
method of Stella et. alA$ The allyl bromide was distilled from 
calcium hydride before use. After the alkylation the product had 
to be separated from the 1,2 addition product and starting 
material by flash chromatography using 12.5% ethyl 
acetate/hexane. The product from the decarboethoxylation step 
was purified by flash chromatography using 5% ethyl
acetate/hexane and Kugelrohr distillation. The monoester was
obtained in 36% overall yield. 1H NMR (CDCI3, 200 MHz) 8 7.17
to 7.32 (m, 5, aromatic), 5.59 to 5.67 (m, 1, -CH2CH-CH2), 4.94 
to 5.04 (m, 2, -CH2CH=CE2.)» 4.01 (qt, 2, J= 7 Hz, -CO2CH2.CH3) , 
3.13 to 3.29 (m, 1, methine), 2,48 to 2.74 (m, 2,
CH(Ph)CH2CH-CH2), 2.35 to 2.43 (m, 2, -CH (Ph) Cli2C02Et), 1.12 (t, 
3, J- 7.2, -C02CH2Cttl); mass spectrum m/z 218 (M+, 5), 177
(11), '144 (24), 135 (100,, 130 (33), 105 (54); IR (neat) 2980,
1734 (OO), 1640 (C-C), 1250, 1161, 1032; Anal, calcd. for 
C14H18O2: C, 77.03; H, 8.31. Found: C, 77.07; H, 8.34.
Ethyl 2-Methyl-3-phenyl-5-hexenoate (10). Placed 
diisopropyl amine (1 equiv.) in 11.5 ml dry THF and cooled to 0°. 
Added 1.83 ml (1 equiv., 1.25 M) of n-butyllithium and stirred at
Scheme II
0° for 30 minutes. Cooled solution to -78° and slowly added .5 
gram of () over 25 minutes and allowed to stir for 30 minutes. 
Added methyl iodide (.157 ml, 1.1 equiv.) over  seven minutes at - 
78° and stirred that temperature for cue and a half hours. 
Allowed flask to warm to room temperature ano ! hen quenched with 
sat. ammonium chloride. The solution wa., taken up in ethyl 
acetate, washed twice with sat. ammonium chloride, once with 
brine, dried (MgS04), and concentrated. The compound was 
purified with flash chromatography using 5% EtOAc/hexane. 
Recovered 377mg (71% yield) of a clear oil. NMR (CDCI3,
200MHz) 8 7.11 to 7.33 (m, 10, aromatic), 5.47 to 5.61 (m, 2,
Cii»CH 2), 4.84 to 5.00 (m, 4, CH-CH^) , 4.18 (qt, 2.24, 7 Hz, -
CC>2Cii2.CH3 of greater diastereomer) , 3.89 (qt, 1.76, J« 7 Hz, -
CO2CH2CH3 of lesser diastereomer), 2.31 to 2.97 (m, 8, 
O2CCJKCH3) CH(Ph) C&2CH-CH2) , 1.29 (t, 3.36, J« 7.1 Hz, -CC>2CH2CJil 
of greater diastereomer), 1.23 (d, 2.64, J« 6.6 Hz, methyl of
lesser diastereomer), .99 (t, 2.64, J« 7.2 Hz, -C02CH2CH2 of
lesser diastereomer), .92 (d, 3.36, J= 6.6 Hz, methyl of greater 
diastereomer); mass spectrum m/z 232 (M+, 5), 191 (10), 187 (7),
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106 (6), 135 (98), 131 (68), 102 (53), 91 (100); IR (neat)
2980, 2936, 1730 (OO), 1642 (O-C), 1453, 1254, 1175 cm'1. Anal.
calcd. for C15H20O2: C, 77.55; H, 8.68. Found: C, 77.58; H,
8.70.
2-Methyl-3-phenyl-5-hexenoic acid (11). The ester () (344
mg) was dissolved in a solution prepared from 9 ml of aqueous
potassium hydroxide and 20 ml of methanol and stirred under
nitrogen 60 hours. The reaction was put at 60° for seven hours 
at the beginning of the reaction and then allowed to return to 
room temperature for the duration. At 60 hours, the methanol was 
removed in vacuo and the basic solution was washed three times 
with diethyl ether. The solution was then acidified to a PH of 3 
with concentrated hydorchloric acid and extracted four times with 
ethyl acetate. The ethyl acetate phases were dried (MgS04) and
concentrated to 270 mg (89% yield) of a clear oil. *H NMR
(CDCI3, 200 MHz) 8 7.10 to 7.33 (m, 10, aromatic), 5.48 to 5.57
(m, 2, CH=CH2), 4.83 to 5.01 (m, 4, CH«CH2.> > 2.39 to 3.09 (m, 8,
H02CCtt(CH3)Cfl(Ph)CH£CH«CH2), 1.23 (d, 3.3, J- 6.9 Hz, methyl of 
greater diastereomer) , .95 (d, 2.7, J- 6.5 Hz, methyl of lesser
diastereomer) ; mass spectrum m/z 204 (M+, 2.5), 186 (2), 175 
(4), 131 (70), 107 (100), 91 (83), 57 (74); IR (neat) 2980
(broad), 1705 (OO) , 1642 <OC) , 1455, 914 cnT1. Exact mass
calcd. for C13H16O2 m/e 204.1150, obsd. m/e 204.1152.
2-Methyl-3-phenyl-5-hexynoic acid (12) . This compound was 
prepared following the same general procedure as Brandsma.*7 The 
alkenoic acid (11) (834 mg) was dissolved in 5 ml of diethyl
ether and cooled to -20°. Bromine (.232 ml, 1.1 equiv.) was 
added to this solution slowly 6ver twenty minutes. As with the 
gamma methyl, a dark brown oil came out of solution and made 
stirring and transfer difficult. Allowed the solution to warm to 
room temperature and added a small portion of THF to dry and
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dissolve the oil, but this did not prove to be very effective. 
Transferred the solution and the oil to an addition funnel with a 
syringe and added to the sodamide suspension in liquid ammonia 
(800 mg in 30 ml NH3, 5 equiv.) over 15 minutes with nitrogen 
purging the system. Allowed to stir with a dry ice/acetone 
reflux condenser maintaining the ammonia level. At one and a 
half hours after the addition of brominated (11), the ammonia was 
allowed to boil off. Dissolved flask contents in water, 
acidified with concentrated HC1, extracted three times with ethyl 
acetate, washed ethyl acetate phases once with brine, dried
(MgS04) , and concentrated to a dark brown oil. The compound was 
purified with flash chromatography using 35% ethyl acetate/hexane 
(1% acetic acid) followed by Kugelrohr distillation to 270 mg 
(33% yield) of a clear oil. lH NMR (CDCI3, 200 MHz) 8 7.19 to
7.36 (m, 10, aromatic), 2.85 to 3.19 (m, 4, H02CCK(CH3)CK(Ph)-), 
2.6 (m, 4, methylene), 1.94 (t, 1.06, J= 2.4 Hz, acetelynic of 
greater diastereomer) , 1.89 (t, .94, 2.5 Hz, acetelynic of
lesser diastereomer), 1.27 (d, 3.18, J= 6.6 Hz, methyl of greater 
diastereomer), .98 (d, 2.82, J= 7 Hz, methyl of lesser
diastereomer); mass spectrum m/z 202 (M+, .5), 187 (.7), 163
(13), 129 (71), 107 (59), 57 (47), 43 (100); IR (neat) 3295,
3031 (broad), 2361, 1707 (OO), 1455, 1289 cm’1. Exact mass
calcd. for C13H14O2 m/e 202.0994, obsd. m/e 202.0994.
3-Methy1-4-phenyl-6-methylene~tetrahydo-2-pyranone (13,14) . 
This compound was prepared using the procedure developed in our
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labs with mercuric trifluoroacetate.18 The aikynoic acid (12) 
(175 mg) was dissolved in 9.3 ml of dry methylene chloride. To 
this solution was added 37 mg (.1 equiv.) of mercuric 
trifluoroacetate, and the solution was stirred at room 
temperature for three and a half hours. Gas chromatography and 
TLC showed a side product forming with a lower retention time by 
GC and a greater Rf by TLC than the two enol lactones that were 
forming. The reaction was quenched by saturated sodium 
bicarbonate and allowed to stir for ten minutes. The solution 
was diluted with water, extracted four times with methylene 
chloride, organic phases washed once with water, dried (MgS04), 
and concentrated to a slightly yellow oil. To purify and 
separate the diastereomers, flash chromatography was performed 
using 12.5% ethyl acetate/hexane. Again separation was not great 
as many mixed fractions were obtained, and the higher Rf impurity 
(Rf“ .42, 15% ethyl acetate/hexane) could not be separated from 
diastereomer I (). Total product (96 mg, 55 % yield). 
Diastereomer I- Upper spot by TLC (Rf* .38, 15% ethyl
acetate/hexane), white crystal (30.1 mg obtained from column), 
mp 48-50 °C, 87% product (), 13% impurity by GC. *H NMR (CDCI3, 
360 MHz) 8 7.26 to 7.39 (m, 3, meta and para of aromatic), 7.19
(m, 2, ortho of aromatic), 4.72 (t, 1, J- 1.3 Hz, vinylic), 4.33 
(s, 1, vinylic), 2.65 to 2.86 (m, 4, -C02Cfl(CH3) Cfl(Ph) Cfl2C-), 1.16 
(d, 3, J- 6.6 Hz, methyl); mass spectrum m/z 202 (M+, 24), 174 
(15). 159 (21), 145 (100), 131 (46), 104 (83); Exact mass calcd. 
for C13H14O2 m/e 202.0994, obsd. m/e 202.0994; Anal, calcd. for
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C13H14O2: C, 77.20; H, 6.98. Found: C, 77.36; H, 6.96. 
Diastereomer II- Lower spot by TLC (Rf~ .30, 15% ethyl
acetate/hexane), white crystal (16.1 mg obtained from column), mp 
60-61 °C. 1H NMR (CDCI3, 360 MHz) 8 7.25 to 7.39 (m, 3, meta and
para aromatic), 7.12 (m, 2, ortho aromatic), 4.77 (s, 1,
vinylic), 4.33 (d, 1, J«* .8 Hz, vinylic), 3.35 (m, 1,
CH(CH3)CH(Ph)CH2-), 2.94 to 3.02 (m, 2, -CE(CH3>CH(Ph)CflH-), 2.81 
(dd, 1, J= 15.5, 6.6 Hz, -CH(Me)CH (Ph)CHE-) 1.04 (d, 3, J- 7.2
Hz, methyl); mass spectrum m/z 202 (M+, 17), 174 (12), 159 (21), 
145 (100), 117 (92), 104 (76); Exact mass calcd. for C13H14O2 m/e 
202.0994, obsd. m/e 202.0994; Anal, calcd. for C13H14O2: C,
77.20, H, 6.98. B’ound: C, 77.21; H, 6.99.
B. Biochemical
General. Proflavin displacement assays were performed using a
Hewlett-Packard 8451A diode array spectrophotometer (UV-visible). 
a-chymotrypsin was obtained from Worthington Biochemical. The
phosphate buffer was prepared by dissolving 1.932 g of NaH2PC>4*H20 
and 5.111 g of Na2HP04 in 500 ml of distilled water making this a 
0.1 M solution, PH 7.2.
Proflavln Displacement Assay. To a solution of 100 H* of ImM <X- 
chymotrypsin at a PH of 3 was added 900 |ll of phosphate buffer and 
100 Hi of 100 \lM proflavin. This solution was referenced, and 
then 10 Hi of 10 mM solution of enol lactone in dimethyl 
sulfoxide at 25° was added. The change of absorbance was then
followed at 4 66 nm, and the semilogarithmic plot of the 
increasing progress curve versus time gave a straight line with a
30
slope of kd.
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